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Abstract
Sodium Butyrate (NaBu) is regarded as a potential reagent for cancer therapy. In this study, a specific breast cancer cell
population that is resistant NaBu treatment was identified. These cells possess cancer stem cell characters, such as the
capability of sphere formation in vitro and high tumor incident rate (85%) in mouse model. Forty percent of the NaBu
resistant cells express the cancer stem cells marker, the CD133, whereas only 10% intact cells present the CD133 antigen.
Furthermore, the endogenous expressing c-MET contributes to the survival of cancer stem cell population from the
treatment of NaBu. The CD133+ group also presents a higher level of c-MET. A combination treatment of MET siRNA and
NaBu efficiently prohibited the breast cancer progression, and the incident rate of the tumor decrease to 18%. This study
may help to develop a new and alternative strategy for breast cancer therapy.
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Introduction
Sodium butyrate (NaBu) is the sodium salt of butyric acid
produced by large intestinal micro flora. As a potent histone
deacetylase (HDAC) inhibitor in vivo, NaBu has been reported to
regulate a large number of genes in cultured mammalian cells [1].
It has been reported that the NaBu induce growth arrest, apoptosis
or differentiation on different cancer cell lines, including breast
cancer cell lines [2]. Since it exhibits cancer chemotherapeutic
potential, NaBu has been considered as a potential regent for
cancer therapy [3]. Recently, It was reported that NaBu induces
breast cancer cell differentiation by regulating b-casein and N-myc
downstream-regulated gene 1 (NDRG1) in breast cancer cells [4].
Caspase-10 also plays an important role in the induction of
apoptosis by NaBu on breast cancer cells [5]. However, cancer is
composed of heterogenerious population of cells and the function
of NaBu on different population needs to be elucidated.
MET oncogene, encodes for the tyrosine kinase receptor for
hepatocyte growth factor, has been shown to be over expressed in
various type of tumor cells [6,7]. It contributes to the invasive
growth of cancer cells through hepatocyte growth factor paracrine
stimulation. Within the intracellular portion of MET, Tyr1234
and Tyr1235, mediates MET biological activity and the key
tyrosine residues in the carboxy-terminal tail, Tyr1349 and
Tyr1356 capable of recruiting downstream adapter proteins with
Src homology-2 (SH2) domains [8]. Several oncogenic pathways
are recruited by the engagement of MET, including Ras-Erk/
mitogen-activated protein kinase (MAPK) pathway, Rac1/Cdc42-
PAK pathway and Gab1-phosphoinositide 3-kinase (PI3K)-Akt
pathway [8,9,10]. Moreover, c-MET may work with WNT or
NOTCH pathways for the self renewal of cancer cells or stem cells
[11].
In breast tumor patient, the relationship between c-MET up-
regulation and tumor progress has been demonstrated [12].
Studies revealed MET overexpreesion correlated with aggressive
phenotype of different cancer, including breast cancer. Indeed, c-
MET has been regarded as a novel target for therapeutic
approaches because of the significant correlation between c-
MET overexpression and a high risk of disease progression
[13,14]. However, the interaction between c-MET and NaBu, the
HDAC inhibitor is not clear. In the present study, we found that c-
MET protects breast cancer cells from the apoptosis induced by
NaBu. Moreover, we also demonstrated that a NaBu- resistant
population expressed a high level of c-MET with cancer stem cells
property. The result also indicated that, although regarded as a
tumor suppressor, NaBu might be not sufficient to remove cancer
stem cells and to prohibit the recurrence of breast cancer.
Results
Anti-tumor efficiency of NaBu was different in MDA-MB-
231 cells and MCF-7 cells
In order to test the tumor suppression effect of NaBu in different
types of breast cancer, two kinds of breast cancer cell lines, the
estrogen receptor negative MDA-MB-231 and the estrogen
receptor positive MCF-7, were rendered the treatment of different
concentration of NaBu (1–5 Mm, data not shown) for 2 days. It
was observed that the MDA-MB-231cell line showed a better
survival rate than the MCF cell line (Fig. 1A–D). Since the most
significant different survival rate between the two cell lines presents
under 4 mM Nabu treatment, we applied this concentration for
studies thereafter. Nearly 30% of MDA-MB-231 cells remained
viable compared with only 16% of MCF-7 cells survived under the
same condition when treated with 4 mM Nabu, as assessed by
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most significant survival rate between the two cell lines, therefore,
we applied this concentration for further studies
Since previous studies demonstrated that NaBu induced cell
apoptosis in MDA-MB-231 and MCF-7 [15,16]. Herein, we
investigated whether the different survival rate between these two
cell lines is caused by their different response to the treatment of
NaBu. Indeed, western blotting results showed higher expression
level of Bad, Bax and Cytosolic Cytochrome C, but weaker
expression level of Bcl-2 in MCF-7 cells than in MDA-MB-231
cells after NaBu treatment (Fig. 1F and Figure S1). These results
suggested that the MDA-MB-231 cells were more resistant to
apoptosis effect after NaBu treatment as compared to MCF-7 cells.
By knocking down the expression of Bad or Bax, the apoptosis
effect of NaBu was attenuated in MDA-MB-231 cells (Figure S2).
These results suggested that the NaBu caused the MDA-MB-231
cells loss by apoptosis induction effect.
c-MET contributed to the survival of breast cancer cells
after the treatment of NaBu
Studies have illustrated that MET, an oncogene that promotes
the progression and invasion of cancer cells, contributes to the cell
proliferation by minimizing the apoptosis [7]. We demonstrated
that higher expression level of MET in MDA-MB-231 cells than in
MCF-7 cells by RT-PCR assay, which was consistent with
previously studies (Fig. 2A) [17].
To confirm that the survival rate differences between MCF-7
and MDA-MB-231 cells result from the difference of MET
expression in the two types of cells, we knocked down expression of
MET in MDA-MB-231 cells by transfection with c-MET siRNA.
After the transduction of MET siRNA, the expression of MET was
diminished (Fig. 2B), while after treatment with NaBu, siMET
transfected MDA-MB-231 cells resulted in a significantly lower
survival rate compared to the NaBu treated con siRNA transfected
cells (control group) (Fig. 2C). It suggested that the survival rate of
con siRNA treated cells and intact cells were similar (data not
shown). On the other hand, after we enhanced the expression of
MET in MCF-7 cells (Fig. 2D), the cell survival rate was increased
from 12% to 26% after treated with NaBu (Fig. 2E). Thus the
oncogene MET helps breast cancer line survival through the
treatment of NaBu. Since MDA-MB-231 cells relatively express
higher MET level, we focused our studies on MDA-MB-231 cells
in the subsequent studies.
NaBu- resistant MDA-MB-231 cell showed cancer stem
cells characteristics
Studies have shown that c-MET is closely related to the cancer
stem cell phonotype and is associated with SDF-1-CXCR4 and
LIF-R-LIF axes for the trafficking of normal and malignant stem
cells [10]. We wondered if the NaBu- resistant population in MDA-
MB-231 cells displayed a higher cancer stem cell capability. Firstly,
we examined the NaBu- resistant population with an elevated
expression of MET compared to the control group (Fig. 3A). This
was consistent with the western blot results (Fig. 3B; we mixed up
figure 3B previously and all of our available data show c-MET
upregulation in NABU treated cells, shown as Figure S3). Since c-
MET helps the NaBu-resistant population survival as we demon-
strated above,therefore,itcould be concludedthat NaBuselected c-
MET positive cells out and enriched them in the dish.
To determine the stem cell capability of NaBu-resistant MDA-
MB-231 cells, sphere formation tests were performed. Firstly, we
confirmed that the con siRNA treated cells have similar sphere
formation ability with intact cells. The con siRNA treated or MET
siRNA treated cells were applied in this experiment. NaBu-
resistant breast cancer cells showed a significantly higher sphere
formation ability in vitro than the con siRNA treated group
(Fig. 3C). As expected, the sphere formation ability of NaBu
resistant MET knock down group was dramatically decreased
(Fig. 3C), comparing to NaBu-resistant con siRNA treated group.
These results suggested that NaBu treatment enriched the c-MET
positive cancer cell population which possesses the breast cancer
stem cell capability.
Afterwards, We employed CD133 for the confirmation of breast
cancer stem cells character of NaBu- resistant population, since
Figure 1. NaBu induced tumor suppression effect was dependent on cancer cell types. (A) to (D) showed the effect of NaBu on breast
cancer cell line MDA-MB-231(A and B) and MCF-7 (C and D). Majority of MDA-MB-231(B) and MCF-7(D) cancer cells were removed by the treatment of
NaBu. Compared with 16% of viable MCF cells, the survival rate of MDA-MB-231 was significantly increased to 30%(E). Immunoblotting result of BAD,
BAX, Bcl-2 and Cytochrome C expression indicated that MDA-MB-231 cells were resistant to the treatment of NaBu by neutralizing its apoptosis effect
compared with MCF-7 cells (F). *P,0.05.
doi:10.1371/journal.pone.0030143.g001
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MET was higher in MDA-MB-231 cell than in MCF-7 cells (A). The expression level of MET in MDA-MB-231 cells were decreased by the treatment of
MET siRNA (B). Silencing MET in MDA-MB-231 cells resulted in a poor survival rate (7%) when the cells were treated by NaBu (C). For MCF-7 cells, while
the MET expression was increased obviously by induction of MET activator (D), the cell survival rate were increased significantly with the presence of
NaBu in culturing medium (26%)(E). *P,0.05.
doi:10.1371/journal.pone.0030143.g002
Figure 3. NaBu-resistant MDA-MB-231 cell showed cancer stem cells character. RT-PCR result indicate that the NaBu- resistant cell
population displayes a higher expression level of MET (A). This was consistent with the western blot results (B). After seeding 10
5 cells in 100 mm
peridish, NaBu- resistant cells showed the strongest sphere formation capability (2.7610
4/dish) when compared with control siRNA treated
goup(1.8610
4/dish)and MET siRNA treated group(0.8610
4/dish)(C). A higher CD133 expression level by western blot in the NaBu- resistant group was
observed(D). More than 40% NaBu- resistant cells were positive for CD133 expression, however, within the control siRNA treated cells, only around
10% cell were positive for CD133(E). the CD133
+ cells expressed higher level of c-MET compare to CD133 negtive cells(F). After treated with NaBu, cell
viability of CD133
+ cells are significantly higher than that of CD133
- cells number . Intact MDA-MB-231 cells are used as control without the treatment
of NaBu (G). *P,0.05.
doi:10.1371/journal.pone.0030143.g003
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We obtained a higher CD133 expression level by western blot in
the NaBu- resistant cell initiated sphere (Fig. 3D). Correspon-
dently, we found that in the NaBu-resistant cell initiated spheres,
40% cells expressed CD133 positively. However, only nearly 10%
cells in control cell initiated spheres presenting CD133 antigen
(Fig. 3E). To elucidate whether c-MET expressed higher in
CD133+ population, we tried to separate CD133+ and CD133-
cells in intact MDA-MB-231 cell initiated spheres by flow
cytometery. The expression of c-MET in these two groups was
checked by western blot. As we expected, the CD133-positive cells
expressed higher level of c-MET, compared to CD133-negative
cells (Figure 3F). To testify whether the CD133-positive and the
CD133-negative cells respond differently to NaBu, We separated
CD133+ and CD133- cells from intact MDA-MB-231 initiated
sphere. The same number (10
4/ml) of the two fraction cells were
cultured with 4mM NaBu in 100 mm dish. Two days later, NaBu
was removed by changing the medium. After one day, MTT assay
was performed. After treated with NaBu, cell viability of CD133
+
cells was significantly higher than that of CD133
- cells number.
Intact MDA-MB-231 cells are used as control without the
treatment of NaBu (Fig. 3G).
NaBu- resistant MDA-MB-231 cell possessed an
increasing tumor initiation ability in vivo
Since the NaBu-resistant group displayed cancer stem cells
property as described above, we subsequently testified the tumor
initiation ability in an animal model. The same number of NaBu-
resistant cells and intact MDA-MB-231 cell was transplanted into
mouse mammary fat pat. Tumors became palpable as early as on
the 5th day in the mice transplanted with NaBu- resistant cells.
However, in the control group, tumors became palpable on the
10th day post transplant. By the day 28th, tumor volume was
significantly different between the two groups (Fig. 4A). Compare
with NaBu treated intact cells, or with MET knock down cells,
tumor volume was significantly smaller in NaBu treated MET
knock down cell transplanted group (Fig. 4A). Meanwhile, we tried
to clarify the tumorigenic effect of MET in the same animal model.
MET knocked down MDA-MB-231 cells were generated before
treated with 4mM NaBu for 2days. The NaBu-resistant MET
knock down cells and con siRNA transfect cells were also
transplanted into the mouse. The tumor incidence in intact
MDA-MB-231 group and con siRNA group was comparable
(Fig. 4B). On the 30
th day, the tumor incidence in NaBu- resistant
MET knock down group was decreased to 18% as compared to
con siRNA transfected cells (Fig. 4B). Again, the MET knock down
resulted in a comparable tumor incidence rate with con siRNA
treated control group (Fig. 4B). These results demonstrated that
NaBu-resistant population of MAD-MB-231 cell has high tumor
initiation ability, while down regulation of MET gene results in
decreasing its tumorigenicity efficiently.
Discussion
It have been well elaborated that NaBu exerts its tumor
suppression effect on several type of cancer, such as, colon cancer,
lung cancer and breast cancer [15,19,20,21]. Therefore, NaBu has
been regarded as a potential cancer therapy regent if one despite
the short life-time of NaBu in the body [20]. In the present study,
we found that, although NaBu induces majority cell death in the
breast cancer cells, the minority cells that share the breast cancer
stem cell characteristics may survive through NaBu selection.
Those cells display higher ability of sphere formation in vitro as well
as higher tumor incidence in animal model. Our studies suggested
that the potential anti-tumor regent NaBu treatment may not be
capable of removing breast cancer efficiently, since the seed of
breast cancer, breast cancer stem cells, may resist from the
treatment.
Our study clarified that the oncogene MET contributed to the
NaBu- resistant effect of breast cancer cell. MET expressing breast
cancer cell population display cancer stem cell characteristics, and
studies illustrated that c-MET is closely related with highly
aggressive cancer cell type. c-MET attenuates the apoptosise effect
induced by NaBu in breast cancer cells. Our results demonstrated
that when cancer cells after treated by the combination of NaBu
and MET siRNA, decreased tumor incidence dramatically in the
mouse model. However, in this study, a cell line was used as a
simplified model to testify the effect of NaBu and c-MET on breast
cancer. Further studies are needed to examine the reaction of
breast cancer cells, especially cancer stem cells, to NaBu and c-
MET in the patient, since cancer stem cells are resident in and
dynamically regulated by its specific micro-environment. Based on
this result and other studies, the MET expression level is different
between the two cancer cell lines, MCF-7 and MDA-MB-231
Figure 4. NaBu- resistant MDA-MB-231 cells displayed a high tumor initiation ability in vivo. Intact MDA-MB-231 and NaBu- resistant
MDA-MB-231 cells were transplanted into NOD/SCID mouse. By the day of 28th, the tumor volume were significantly different. Moreover, tumor
became palpable as early as on the 5th days in the NaBu- resistant MDA-MB-231 cell transplanted group whereas on the 10th day in the control
group(A). Compared with NaBu treated intact cells, or with MET knock down cells, tumor volume was significantly smaller in NaBu treated MET knock
down cell transplanted group (A). The tumor incident data were collected on the 30th day after transplanting cancer cells. The NaBu- resistant MDA-
MB-231 cell transplanted group resluted in a similar tumor incident rate as the intact MDA-MB-231 group(85%). Down regulation of MET with a
treatment of NaBu leads to decrease the tumor incident rate effectively(18%), although con siRNA teated group resulted in a similar tumor incident
rate with the intact cancer cell group(83%). *P,0.05.
doi:10.1371/journal.pone.0030143.g004
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receptor presentation and the expression of c-MET. For the c-
MET low expressing cells, like MCF-7, it needs to be clarified
whether another protective pathway exist to support cancer cells
resisting the treatment of NaBu.
A NaBu-resistant population of breast cancer cells was identified
in this study. This population of cells possesses cancer stem cells
capability in vitro and in vivo. Although NaBu is regarded as a
potential anti cancer substance, the endogenous expressing c-MET
cancer stem cell population survived after the treatment of NaBu.
A combination treatment of MET siRNA and NaBu administra-
tion can efficiently eliminate breast cancer. This study may help to
develop a new strategy for breast cancer therapy.
Materials and Methods
Cell cultures
Human breast cancer cell MDA-MB-231 (ATCC, Manassas,
VA) were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM; Gibco BRL, Grand Island. NY) supplemented with 10%
heat-inactivated fetal bovine serum (FBS, Gibco), penicillin
(100 U/ml, Gibco) and streptomycin (100 mg/ml, Gibco) at
37uC in a CO2 atmosphere. NaBu (Sigma, ST. Louis, MO)was
dissolved in the culture medium to the indicated concentration for
treating breast cancer cells.
MTT assay
The cell survival rate was quantified by MTT assay. After
transfected with MET siRNA, cells were allowed to recover in
fresh medium. One day later, medium were changed with or
without NaBu(4mM). After 2 days, cells were washed in PBS and
recovered in fresh medium for another two days. Sicontrol were
used as siRNA transfection control. In some experiments, the
intact MDA-MB-231 cells and intact MCF-7 were engaged to test
the effect of NaBu on these two cell lines as indicated. MTT (50 ml
of 2 mg/ml) in 16PBS was added to each dish, and the cells were
incubated for 4 hrs at 37uC. The plates were then centrifuged at
500 6 g for 10 min, and DMSO (120 ml, Sigma) was added to
each well and incubated 1 hr on an orbital shaker. The A570 nm
was determined using an Ultra-microplate reader (ELx 808; Bio-
Tek Instruments, Winooski, VT).
Sphere- forming assays
For the colony formation assay, studies were preformed
following the previous report [22].,con siRNA(Control siRNA,
Santa Cruz, CA) treated MDA-MB-231 cells were treated by
4mM NaBu. After two days, cells were allowed to recover for
2days in fresh medium without NaBu. To testify the effect of c-
MET on the sphere formation ability of the Nabu resistant cells,
the MET siRNA (Santa Cruz) treated MDA-MB-231 cells were
treated by 4mM NaBu for 2days. After recovering for 2days in
fresh medium, the cells were engaged in sphere formation assay. In
detail, cells were trypsinized to generate single-cell suspensions and
counted by a hemocytometer. Single-cell suspensions (105 cells per
100 mm dish) were plated with an ultralow attachment surface.
Three dishs were seeded for each cell line, and triplicate
experiments were performed. Tumor spheres were counted and
images of each well were taken on day 9. Immediately after the
cells were seeded, each well was checked under the microscope to
verify the sparseness of each spherical culture, and only wells
containing single-cell suspension with no cell cluster were chosen
for tumor-sphere counting after 9 days. Colonies of at least 60 mm
in diameter (determined by using an eyepiece graticule with
crossed scales) were counted on day 9 after plating. Con siRNA
treated MDA-MB-231 cells were used as control group.
Western blot analysis
Protein was extracted from the cells after culturing in the
indicated conditions. After measuring the protein concentrations
of homogenized lysates, 10 mg of protein extracted from cancer
cells was separated by 10% SDS–PAGE and transblotted onto a
polyvinylidene fluoride (PVDF) membrane. After blocking in a
powdered nonfat milk solution (5% in PBS) with 0.05% Tween-20,
the blot was incubated with a polyclonal rabbit anti- human Bcl-2-
associated death promoter (BAD) antibody (Cell Signaling,
Danvers, MA),a rabbit anti- human BAX antibody (Cell
Signaling), a rabbit anti- human Bcl-2 antibody (Cell Signaling),
a rabbit anti- human Cytochrome C antibody (Cell Signaling), a
rabbit anti-human CD133 antibody (Cell Signaling) and a rabbit
anti-human beta– actin antibody (Cell Signaling) at 1:1000
dilutions in 5% blocking solution over night at 4uC. An anti-
rabbit IgG antibody at a dilution of 1:5000 was used as a
secondary antibody. The results were detected with an enhanced
chemiluminescence kit (ECL; Amersham Bioscience/GE Health-
care, Little Chalfont, UK).
Reverse transcription (RT)- polymerase chain reaction
(PCR)
Total RNA was isolated with TRIzol reagent (Invitrogen).
Briefly, 500 ng of total RNA was reverse transcribed into cDNA
using Avian Myeloblastosis Virus (AMV) reverse transcriptase
(Takara, Ohtsu, Japan). PCR was conducted in a 20-mL reaction
mixture containing 1 mL of cDNA template and 0.5 mM
oligonucleotide primers. Primer sequences are:
human MET, forward 59 –CATGCCGACAAGTGCAGTA-
39, reverse 59- TCTTGCCATCATTGTCCAAC -39,
human beta-actin, forward 59- GACGAGGCCCAGAGCA-
AG- 39, reverse 59- ATCTCCTTCTGCATCCTGTC- 39.
RNA interference
Transfection of small interfering RNA (siRNA) into cells was
conducted when the cells reached 70% confluence. The siRNAs of
MET and a non-targeting control were purchased from Santa
Cruz Biotechnology. Experiments were conducted using Dharma
FECT1 (Dharmacon, Chicago, IL) as a transfection agent and
siRNAs at a concentration of 100 mmol/L. Experiments were
conducted according to the manufacturers’ instructions.
MET Retroviral Infections
Recombinant retroviruses were constructed by subcloning full-
length human cDNA of Met into the retroviral expression vector
pLNCX2 (Clontech, CA), which carries a neomycin phospho-
transferase cassette. A retroviral expression vector carrying the
cDNA of human placenta alkaline phosphatase (pLAPSN) served
as a control. Experiments were conducted according to the
manufacturers’ instructions and previous report [23].
Animal studies
All mouse studies were performed in accordance with protocols
approved by the Animal Care and Use Committee at Southeast
University (Approval ID: SEU-20100921-2). SCID mice were
housed under pathogen-free conditions and were given autoclaved
food and water. MDA-MB-231 cells were exposed to NaBu for 2
days. The intact MDA-MB-231cells were used as control. After
determining the cell viability by trypan blue exclusion test, 26106
cells were injected into mammary fat pad in a 100 uL volume of
c-MET Protects Cancer Cells from Apoptosis
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of age and 10 mice for each group. Tumors were measured using
precision calipers twice weekly. Tumor volume was calculated at:
volume = (length 6width
2)/2.
Flow cytometry
After 3 washes with PBS, cells that were treated with NaBu and
intact cells were detached with trypsin (Gibco) for 10 min at 37uC.
For cell surface antigen phenotyping, floating and detached
spindle-shaped cells were stained with fluorescent antibody CD133
(Becton–Dickinson, San Jose, CA, USA). Analyses were performed
with FACS Calibur (Becton–Dickinson, NY, USA). CD133
positive cells were sorted by DAKO cytomation (DAKO,
Carpinteria, CA).
Statistical analyses
Data are presented as means 6 standard error (SD) in
quantitative experiments. The differences between groups were
analyzed using the unpaired Student’s t-test. P values ,0.05 were
considered significant.
Supporting Information
Figure S1 The expression of Bad in MDA-MB-231 and
MCF-7 are different. To confirm the a decrease in Bad
expression in the MDA-MB-231 cells compared to the MCF-7
cells, triplicate studies were performed. The expression of BAD in
MDA-MB-231 and MCF-7 were detected by western blot(A) .The
results were quantitated and presented a significant difference in
Bad expression in between MDA-MB-231 and MCF-7cells(B).
(TIF)
Figure S2 Bad or Bax knock- down attenuated the
apoptosis effect of NaBu in MDA-MB-231 cells. The
expression BAD and BAX were knock down by siBAD and siBAX
respectively(A). BAD knock-dwon could moderatly prohibit the
apoptosis effect of NaBu in the cells. However, BAX knockdown
could protect cancer cells from the treatment of NaBu effectively
as indicated by MTT assays(B).The level Cytochrome C examined
by western blot was consistent with this result(C).
(TIF)
Figure S3 NaBu resistant cells presented a higher
expression of c-MET. To confirm that NaBu resistant cells
give a higher expression of c-MET, We did multiple experiments
to confirm that c-MET expression was enhanced in NaBu resistant
MDA-MB-231 cell population.
(TIF)
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